Inovio adds to corporate update-stoked rally

Inovio Pharmaceuticals (INO +27.0%) is up on over 80% higher volume. Shares have rallied 73% since Monday’s corporate overview virtually presented by CEO Joseph Kim at H.C. Wainwright’s Global Investment Conference. COVID-related highlights:

DNA medicines, made via a process called SynCon, deliver optimized plasmids into cells with its handheld Cellectra device which employs a brief electrical pulse to reversibly open small pores in the cells to allow the plasmids to enter (intramuscular or intradermal administration).

DNA vaccine has thermal stability with a five-year shelf life at refrigeration conditions (characteristic of point-of-care locations) and a one-year shelf life at stabilized room temperature.

Phase 1 data on COVID-19 vaccine candidate INO-4800 showed both neutralizing antibodies and T cell responses in all 40 participants. Results have been submitted for publication, hopefully in the next few weeks.

Results from a challenge study in non-human primates 13 weeks after the last shot showed faster clearance of the coronavirus in both the lower lung and in the nasal passages. Strong neutralizing antibody and T cell responses were observed.

Phase 2/3 studies on tap in the U.S. this month. Confident that external funding will be sufficient.

Study in South Korea ongoing. Chinese regulators signed off on a study there. Recruitment should commence shortly.

Certain other COVID-19 vaccine developers are also enjoying a spike in buying: Novavax (NVAX +10.9%), Vaxart (VXRT +9.5%), iBio (IBIO +7.2%), Altimmune (ALT +13.8%), Moderna (MRNA +3.5%), Heat Biologics (HTBX +15.2%)

https://seekingalpha.com/news/3614685-inovioplus-27-adds-to-corporate-update-stoked-rally